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Background: In limited resource settings, sputum smear conversion at the end of the intensive phase of
tuberculosis treatment is an indicator not only of patients’ response to treatment, but also of anti-tuberculosis
program performance. The objective of this study was to identify factors associated to sputum smear non-conversion
at the end of the intensive phase of treatment, and the effect of smear non-conversion on the outcome of
smear-positive pulmonary tuberculosis patients.
Method: This retrospective cohort study was carried out on data of patients treated in the Diagnostic and
Treatment Centre of Baleng, West-Cameroon from 2006 to 2012. Logistic regression models were used to
evaluate the association of socio-demographic and clinical factors with delay in sputum smear conversion,
and the association of this delay with treatment outcomes.
Result: Out of 1425 smear-positive pulmonary tuberculosis patients treated during the study period, 1286
(90.2%) were included in the analysis. Ninety four (7.3% CI: 6.0- 8.9) patients were identified as non-converted
at the end of the intensive phase of treatment. Pre-treatment smears graded 2+ and 3+ were independently
associated to delay in smear conversion (p < 0.01). Years of treatment ranging from 2009 to 2012 were also
associated to delay in smear conversion (p < 0.02). Delay in smear conversion was significantly associated to
failure [Adjusted Odd Ratio (AOR):12.4 (Confidence Interval: CI 4.0- 39.0)] and death, AOR: 3.6 (CI 1.5- 9.0).
Conclusion: Heavy initial bacillary load and treatment years ranging from 2009 to2012 were associated to
sputum smear non-conversion at the end of the intensive phase of TB treatment. Also, delay in smear conversion
was associated to unfavorable treatment outcomes. Patients with heavy initial bacillary load should thus be closely
monitored and studies done to identify reasons for the high proportion of non-conversion among patients treated
between 2009 and 2012.
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Tuberculosis (TB) remains one of the world’s deadliest
communicable diseases [1]. In 2013, an estimated 9.0 mil-
lion people developed TB and 1.5 million died from the
disease [1]. The management of this disease is a great
challenge in developing countries because resources are
limited, health systems are weak and the rate of HIV in-
fection is high.
According to the WHO, all TB patients should be
monitored during anti-tuberculosis treatment to assess
their response to therapy [2]. The monitoring basically
concerns body weight and sputum smear examination
which should be done, among others, at the end of the
intensive phase of treatment [2]. Despite the low positive
predictive value of sputum smear examination during
treatment, it has been documented to be well correlated
to smear culture [3] and the proportion of smear-
positive patients with sputum smear conversion at the
end of the intensive phase is an indicator of TB program
performance [3].
Non-conversion of sputum smear at the end of the in-
tensive phase of treatment has been documented to be
associated with unfavorable outcomes, more specifically
with default and failure [4-8]. Therefore, the knowledge
of associated risk factors to delay in sputum smear conver-
sion at the end of the initiation phase of anti-tuberculosis
treatment is necessary for care providers to prevent
unfavorable outcomes. This study, done in a major
Diagnostic and Treatment Centre (DTC) in Bafoussam,
West-Cameroon had as objective to identify the risk fac-
tors of sputum smear non-conversion at the end of the
intensive phase of treatment, and the effects of smear
non-conversion on the outcome of SPPTB patients.Figure 1 Algorithm of repartition of Tuberculosis patients treated inMethods
Study design
It was a retrospective cohort study based on documen-
tary review of smear-positive pulmonary TB patients
registered at the DTC of Baleng, from 2006 to 2012. The
main factor of interest was the non-conversion of spu-
tum smear at the end of the intensive phase of anti-
tuberculosis treatment and the effects were the different
outcomes of patients at the end of treatment. Patients
included in the analysis were those who had completed
at least the intensive phase of anti-tuberculosis treat-
ment (see Figure 1). Patients with unknown data for the
main variables of interest were excluded from the study.
Study site
The Diagnostic and Treatment Centre of Baleng is the
largest TB treatment centre of the Cameroonian West
Region. It is a public centre that covers a population of
about 20000 persons. The centre also receives patients
from other parts of the country, especially the West,
Littoral and Centre Regions [9]. TB case management is
done there according to national guidelines which have
been conceived from international guidelines [4].
Tuberculosis control in Cameroon
In Cameroon, TB diagnosis is firstly based on clinical
suspicion. Suspected cases are therefore referred to one
of the 238 DTCs that cover the whole country. In these
TB DTCs, patients are first of all classified according to
the anatomical site of TB. In this way, pulmonary and
extra-pulmonary TB are distinguished. Pulmonary TB
cases are subsequently classified according to bacterio-
logical results. Bacteriology refers to the smear status ofDTC of Baleng from 2006 to 2012.
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observation of M. tuberculosis after staining using Ziehl
Neelsen’s technique. After this, pulmonary TB cases are
classified into smear-negative pulmonary TB (smear con-
tains no AFB in 100 fields) and smear-positive pulmonary
TB (SPPTB) groups. Smear grading of SPPTB cases is as
follows: 1+ (10–99 acid-fast bacilli (AFB) in 100 fields), 2+
(1–9 AFB/field in at least 50 fields), and 3+ (>10 AFB/field
in at least 20 fields).
Whatever the clinical form of TB, all patients should
undergo two phases of treatment: intensive/initiation
phase and continuation phase. The length of the inten-
sive phase depends on patients’ previous history of anti-
tuberculosis treatment (2 months for new patients and
3 months for previously treated patients).
In Cameroon, the implementation of Direct Observed
Treatment (DOT) recommended by the WHO is too
limited because DTCs are few (1 DTC for about 90000
habitants) and patients bear the indirect cost of treat-
ment. The national program recommends to provide
drugs to patients on a weekly basis during the intensive
phase and on a monthly basis during the continuation
phase of the treatment. Treatment consists of a two
month intensive phase of daily rifampicin (R), isoniazid
(H), pyrazinamide (Z) and ethambutol (E), followed by a
four month continuation phase of daily R and H on out-
patient basis. However, a very limited number of patients
are hospitalized during the intensive phase of treatment.
At the end of the intensive phase of treatment, smears
examination should be done for each SPPTB case. De-
pending on the results, patients can be classified into two
groups: (1) Sputum smear conversion at the end of the in-
tensive phase of treatment and (2) Sputum smear non-
conversion at the end of the intensive phase of treatment
(patients with persistently positive smears). Also, smear
examination can be done during treatment to assess re-
sponse to treatment.
At the end of follow-up, patients were classified in sev-
eral groups, according to outcomes of treatment and
drug-susceptible TB [1].
1. Cured: A patient who was initially sputum
smear-positive but was smear-negative in the last
month of treatment, and on at least one previous
occasion
2. Died: A patient who died from any cause during
treatment
3. Failed: A patient who was initially sputum
smear-positive and remained positive at month 5
or later during treatment
4. Defaulted: A patient whose treatment was
interrupted for two consecutive months or more.
5. Transfer: A patient who was transferred to another
DTC during TB treatment.Data analysis
Data were collected from patients’ registers at DTC Baleng
from 2006 to 2012. The main variables collected were
socio-demographic and clinical characteristics of pa-
tients, clinical presentation of TB, results of sputum smear
examination prior to and during anti-tuberculosis treat-
ment and the patients’ outcomes at the end of follow-up.
Statistics were analyzed with Epi info software version
3.5.4 from the Center for Disease Control and Prevention
(CDC). Chi square or Fisher’s exact tests were used to
compare proportions. A backward logistic regression was
used to identify the independent risk factors for bacterio-
logical non-conversion at the end of the intensive phase of
treatment. The same logistic regression method was used
to assess the effects of sputum smear non-conversion, at
the end of the intensive phase of treatment, on patients’
outcomes. A p-value <0.05 was used to characterize sig-
nificant results.
As data were collected in patients’ registers, no informed
consent was necessary. The study was approved by the ad-
ministrative authorities of the Diagnostic and Treatment
Centre of Baleng and the Mifi Health Committee.
Results
Between 2006 and 2012, 1786 TB patients presented to DTC
Baleng. Among them, 133 (7.4%) were extra-pulmonary
cases and 228 (12.8%) were smear-negative pulmonary TB
cases. Out of 1425 smear-positive pulmonary TB cases,
1286 (90.2%) were included in the analysis.
The mean age of patients included in the analysis was
36.7 (SD: 14.7); 772 (60% CI: 57.3- 62.7) patients were male
while 514 (40%) were female. One hundred and five (8.4%)
patients had previous history of TB treatment. Results of
pre-treatment smear examination were as follows: 1+
grade for 182 (14.2%) patients, 2+ for 589 (45.8%) patients
and 3+ for 515 (40.0%) patients. Among patients whose
HIV status was available (83.4%), 238 (22.1%) were HIV
positive while 839 (77.8%) were HIV negative; 42.0% of
HIV positive patients were under antiretroviral treatment.
Ninety four (7.3% CI: 6.0- 8.9) patients had non-converted
sputum smear at the end of the intensive phase of treat-
ment whereas 1192 (92.7 CI: 91.1- 94.0) patients had con-
verted sputum smear at the same time; these details are
presented in Figure 1.
Table 1 compares the socio-demographic and clinical
characteristics of patients with and without persistently
positive sputum smear at the end of the intensive phase
of anti-tuberculosis treatment. This univariate analysis
showed that 2+ (OR = 7.1 CI: 1.7- 29.5) and 3+ (OR = 9.5
CI: 2.2- 39.3) pre-treatment smear grades, and years of
consultation from 2009 to 2012 (p < 0.01) were signifi-
cantly associated to sputum smear non-conversion at the
end of the intensive phase of treatment. Multivariate logis-
tic regression analysis presented in Table 2 indicated that
Table 1 Characteristics of sputum smear-positive tuberculosis patients, comparing the end of intensive treatment
phase non-converters (delayed converters) with converters in CDT of Baleng, 2006–2012
Characteristics Delayed converters Converters Crude odd ratio
(95% confidence interval)
p value
(n = 94) n (%) (n = 1192) n (%)
Age 33 years old 55 (58.5) 582 (48.8) 1.5 (0.9- 2.3) 0.04
Male sex 62 (66.0) 710 (59.6) 1.3 (0.8- 2.0) 0.22
Years
2006 7 (7.4) 208 (17.5) Reference -
2007 1 (1.1) 147 (12.3) 0.2 (0.02- 1.7) 0.14
2008 6 (6.4) 180 (15.1) 0.9 (0.3- 3.0) 0.9
2009 26 (27.7) 178 (14.9) 4.3 (1.8- 10.2) <0.01
2010 15 (16.0) 153 (12.8) 2.9 (1.2- 7.3) <0.01
2011 20 (21.3) 211 (17.7) 2.8 (1.2- 6.8) 0.02
2012 19 (20.2) 114 (9.6) 4.9 (2.0- 12.1) <0.01
Positive HIV status 20 (23.5) 218 (22.0) 1.1(0.6- 1.8) 0.74
ART* treatment 7 (38.9) 74 (42.3) 0.9 (0.3- 2.3) 0.78
Previous tuberculosis treatment history 8 (8.8) 97 (8.4) 1.1 (0.5- 2.2) 0.50
Initial smear grading
1+ 2 (2.1) 180 (15.1) Reference -
2+ 43 (45.7) 546 (45.8) 7.1 (1.7- 29.5) <0.01
3+ 49 (52.1) 466 (39.1) 9.5 (2.3- 39.3) <0.01
*Antiretroviral treatment.
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independently associated to delayed smear conversion at
the end of the intensive phase of treatment. Moreover,
having a previous history of tuberculosis treatment was
not associated to persistently positive sputum smear at the
end of the intensive phase (p = 0.5).Table 2 Odds Ratio and p-value of associated risk factors
of sputum smear non conversion at the end of intensive
phase of treatment determined from multivariable
logistic regression model
Characteristic Adjusted odd ratio
(95% confidence interval)
p value
Age 33 years old 1.5 (0.9- 2.4) 0.07
Male sex 1.2 (0.7- 1.9) 0.55
Years of consultation
2006 Reference -
2009 4.4 (1.8- 10.4) <0.01
2010 3.1 (1.2- 8.0) 0.02
2011 3.5 (1.4- 8.5) <0.01
2012 5.4 (2.2- 13.4) <0.01
Initial smear grading
1+ Reference
2+ 9.9 (2.4- 42.4) <0.01
3+ 10.6 (2.5- 44.5) <0.01At the end of individual follow-up, 1119 (87.0% CI: 85.0-
88.8) patients were cured; 43 (3.3% CI: 2.4- 4.5) died; 17
(1.3% CI: 0.8- 2.2) failed, 52 (4.0% CI: 3.1- 5.3) defaulted
and 55 (4.3% CI: 3.3- 5.6) were transferred to other DTCs.
As shown in Table 3, univariate analysis associated
non-conversion of sputum smear at the end of the inten-
sive phase of treatment with failure (OR = 7.9 CI: 2.8-
22.1) and death (OR = 3.3 CI: 1.7- 7.4) of SPPTB patients.
On the contrary, delay in sputum smear conversion at the
end of the intensive phase of anti-tuberculosis treatment
was not significantly associated to default (p = 0.56)
and transfer (p = 0.29). After adjustment by multivari-
ate logistic regression analysis (Tables 4 and 5), persist-
ently positive sputum smear at the end of the intensive
phase of anti-tuberculosis treatment remained associated
to failure (AOR = 11.2 CI: 3.5- 35.2) and death (1OR = 3.7
CI: 1.5- 9.0).
Discussion
The first objective of this study was to identify the risk fac-
tors of sputum smear non-conversion at the end of the
intensive phase of treatment. Analysis done on socio-
demographic and clinical data of SPPTB treated in the
DTC of Baleng between 2006 and 2012 showed that high
pre-treatment smear grades (2+ and 3+) and treatment
years between 2009 and 2012 were significantly and inde-
pendently associated to delay in sputum smear conversion
at the end of the intensive phase of treatment.
Table 3 Univariable analysis of association between sputum smear non conversion and final outcomes of smear
positive pulmonary tuberculosis in CDT* of Baleng, 2006- 2012
Characteristics Delayed converters Converters Crude odd ratio
(95% confidence interval)
p
value(n = 94) n (%) (n = 1192) n (%)
Cured 72 (76.6) 1047 (87.8) Reference -
Died 8 (8.5) 35 (2.9) 3.3 (1.5- 7.4) <0.01
Failed 6 (6.3) 11 (1.0) 7.9 (2.8- 22.1) <0.01
Defaulted 3 (3.3) 49 (4.1) 0.9 (0.3- 2.9) 0.56
Transferred 5 (5.3) 50 (4.2) 1.4 (0.6- 3.8) 0.29
*Diagnostic and Treatment Centre.
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data collected from patients’ registers; therefore potential
risk factors not found in the registers were not assessed.
The proportion of smear-positive patients with sputum
smear non-conversion at the end of the intensive phase
is an indicator of TB program performance [3]. During
the study period, 7.3% of SPPTB patients had delayed
sputum smear conversion at the end of the initial phase
of treatment. Studies done in many settings have shown
that proportions of sputum smear non-conversion at the
end of the intensive phase of TB treatment range from
5% to 32% [8,10-13]. Many reasons can explain the non-
conversion of sputum smear at the end of the intensive
phase of TB treatment. First of all, non-viable bacteria
remain visible by microscopy. Ideally, culture is the best
method to evaluate the viability of M. Tuberculosis [14].
Unfortunately, this method can’t be used in field condi-
tions, especially in limited settings such as in developing
countries. However, a study has shown a good correlation
between culture and sputum acid-fast bacilli smear [5].
Therefore, the use of microscopic observation to evaluate
the non-conversion rate at the end of the intensive phase
of treatment can be acceptable. Other potential explana-
tions for non-conversion of sputum smear at the end of
the intensive phase of TB treatment are: poor supervision
of the initial phase of therapy, poor patient adherence,
poor quality of anti-TB drugs, doses of anti-TB drugs
below the recommended range, co-morbid conditions,Table 4 Multivariable logistic regression analysis
accessing the association between sputum smear non
conversion at the end of intensive phase of TB treatment
and treatment failure in DTC* of Baleng, 2006–2012
Characteristic Adjusted odd ratio
(95% confidence interval)
p value
Male sex 1.9 (0.6- 6.2) 0.30
Age˃ 33 0.6 (0.2- 1.6) 0.29
Previous tuberculosis treatment
history
11.2 (3.5- 35.3) <0.01
Non conversion of sputum smear
at the end of intensive phase
12.4 (4.0- 39.0) <0.01
*Diagnostic and Treatment Centre.drug-resistant M. tuberculosis that is not responding
to first-line treatment and heavy initial bacillary load [4].
Heavy initial bacillary load has been documented (as in
our study) as an important risk factor of delay in sputum
smear conversion at the end of intensive phase of TB
treatment [6,7,15-17]. So, to avoid non-conversion at the
end of the initial phase of TB treatment, patients should
be diagnosed early and treated. And moreover, further
studies are needed to identify risk factors of diagnostic
and treatment delay among suspected TB patients and
their effects on initial bacillary load.
Previous studies have identified older age [9,18] and
previous TB treatment history [7,18] as significant risk
factors of sputum smear non-conversion at the end of
the intensive treatment phase. In this study however,
these associations were not significant. This may be due
to sample fluctuation. In contrary to older age and previ-
ous TB treatment history, years of treatment ranging
from 2009 to 2012 were significantly associated to spu-
tum smear non- conversion at the end of the intensive
phase of treatment. This can be the consequence of aug-
mentation of drug-resistant M. tuberculosis that is not
responding to first-line treatment or a change in TB case
management compared to previous years. Further stud-
ies are thus necessary to verify these hypotheses.
The second objective of this study was to evaluate the
association between sputum smear non-conversion at
the end of the intensive phase of treatment and the final
outcomes of patients. Results have shown that sputumTable 5 Multivariable logistic regression accessing the
association between sputum smear non conversion at the
end of intensive phase of TB treatment and patients’




Male sex 1.2 (0.6- 2.7) 0.54
Age˃ 33 1.4 (0.6- 2.9) 0.41
Positive HIV status 6.8 (3.3- 14.0) < 0.01
Non conversion of sputum smear
at the end of intensive phase
3.6 (1.5- 9.0) < 0.01
*Diagnostic and Treatment Centre.
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failure and death. Many previous studies have established
the association between sputum smears non-conversion
and unfavorable final treatment outcomes, especially fail-
ure [6,7,19-21]. Failure is generally the main outcome
identified individually during evaluation of sputum smear
non-conversion effects on final TB cases outcomes. This
can be due to the small number of deaths, defaults and
transfers among cohorts of TB patients in general and
particularly among those who complete the intensive
phase of treatment [22,23]. However, this study has shown
that smear non-conversion is associated to TB patients’
death. This emphasizes the need to reduce the proportion
of sputum smear non-conversion, thereby preventing un-
favorable outcomes.
Conclusion
Heavy initial bacillary load and treatment years ranging
from 2009 to 2012 were associated sputum smear non-
conversion at the end of the intensive phase of treatment
among smear-positive pulmonary TB patients who pre-
sented in the Baleng Diagnostic and Treatment Centre
from 2006 to 2012. Delay in smear conversion was asso-
ciated to failure and death. Patients with heavy initial ba-
cillary load should be closely monitored to prevent
sputum smear non-conversion at the end of the intensive
phase of treatment and unfavorable outcomes. Moreover,
further studies are needed to identify risk factors of heavy
initial bacillary load among smear-positive pulmonary tu-
berculosis patients.Abbreviations
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